Daehan New Pharm Co. Ltd (054670) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.034x

Based on the latest financial reports, Daehan New Pharm Co. Ltd (054670) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.43 Billion ≈ $3.00 Million USD) by net assets (₩129.44 Billion ≈ $87.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Daehan New Pharm Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Daehan New Pharm Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 054670 liabilities breakdown for a breakdown of total debt and financial obligations.

Daehan New Pharm Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Daehan New Pharm Co. Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Mandom Indonesia Tbk JK:TCID	0.032x
MMP Industries Limited NSE:MMP	0.079x
HAZER Group Ltd AU:HZR	-0.222x
Gedeon Richter PLC LSE:0QFP	0.038x
CHINA MAPLE LE.ED.HD0005 F:CML1	N/A
Complete Solaria, Inc NASDAQ:SPWR	0.057x
Globe Metals & Mining Ltd AU:GBE	-0.048x
Zakłady Lentex SA WAR:LTX	0.038x

Annual Cash Flow Conversion Efficiency for Daehan New Pharm Co. Ltd (2014–2024)

The table below shows the annual cash flow conversion efficiency of Daehan New Pharm Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Daehan New Pharm Co. Ltd (054670) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩125.44 Billion ≈ $85.01 Million	₩18.95 Billion ≈ $12.84 Million	0.151x	+31.44%
2023-12-31	₩109.36 Billion ≈ $74.11 Million	₩12.57 Billion ≈ $8.52 Million	0.115x	-16.99%
2022-12-31	₩102.96 Billion ≈ $69.77 Million	₩14.25 Billion ≈ $9.66 Million	0.138x	-31.16%
2021-12-31	₩82.47 Billion ≈ $55.89 Million	₩16.58 Billion ≈ $11.24 Million	0.201x	-15.19%
2020-12-31	₩57.13 Billion ≈ $38.72 Million	₩13.55 Billion ≈ $9.18 Million	0.237x	-36.75%
2019-12-31	₩61.07 Billion ≈ $41.38 Million	₩22.89 Billion ≈ $15.51 Million	0.375x	-21.12%
2018-12-31	₩43.08 Billion ≈ $29.19 Million	₩20.47 Billion ≈ $13.87 Million	0.475x	+1113.94%
2017-12-31	₩51.72 Billion ≈ $35.05 Million	₩-2.42 Billion ≈ $-1.64 Million	-0.047x	-138.14%
2016-12-31	₩71.20 Billion ≈ $48.25 Million	₩8.75 Billion ≈ $5.93 Million	0.123x	+21.58%
2015-12-31	₩77.20 Billion ≈ $52.32 Million	₩7.80 Billion ≈ $5.29 Million	0.101x	-25.43%
2014-12-31	₩73.89 Billion ≈ $50.07 Million	₩10.02 Billion ≈ $6.79 Million	0.136x	--

About Daehan New Pharm Co. Ltd

KQ:054670 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$67.63 Million

₩99.79 Billion KRW

Market Cap Rank

#20708 Global

#1251 in Korea

Share Price

₩7110.00

Change (1 day)

-0.14%

52-Week Range

₩6380.00 - ₩8380.00

All Time High

₩21012.38